Chronic Helicobacter pylori infection is the cause of peptic ulcers in a subpopulation of individuals and a risk factor for the development of gastric cancer. A vaccine against H pylori infection can prevent the acquisition of the infection and protect against reinfections. Clinical trials to date evaluating the efficacy of H pylori vaccines in human challenge models have shown moderate to poor protection with difficulties in predicting efficacy. Thus, while further studies are needed to design an effective vaccine, we also need to find relevant correlates for vaccine efficacy.
| INTRODUC TI ON
Helicobacter pylori are spiral-shaped gram-negative bacteria that persistently colonize the gastric mucosa of over 50% of the world's population. Infection is associated with the development of gastrointestinal disorders such as peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma in sub-populations of individuals. 1 The role of chronic H pylori infection and inflammation in the etiology of gastric cancer classifies H pylori a class I carcinogen, according to the World Health Organization. 2 Natural infection does not induce protective immunity in a majority of infected individuals, and the infection can persist for decades with a mucosal infiltration of immune cells such as dendritic cells (DCs), macrophages, granulocytes and lymphocytes mediated by secreted cytokines and chemokines. 3, 4 Protective immunity against H pylori infection can instead be induced by mucosal vaccination resulting in the reduction of bacterial load compared to sham-vaccinated mice. 5, 6 Vaccine-induced reduction in bacterial load has been shown to largely depend on migration of CD4 + Th1 and Th17 cells, mast cells and neutrophils to the stomach mucosa but not CD8 + T cells or B cells. [6] [7] [8] [9] Since H pylori infects via the mucosal route, it would be desirable that the vaccine is also administered via the mucosal route to generate local immune responses that could protect against reinfection. In this regard, the sublingual (under the tongue; SL) and intragastric (IG) routes of vaccination have been reported as the most relevant routes for mucosal vaccination against H pylori infection due to their potential to induce mucosal CD4 + T-cell immune responses and cytokine secretion in the stomach which correlated with protection. 6 The induction of mucosal immune responses against H pylori antigens requires a mucosal adjuvant, and cholera toxin (CT) has been included as an adjuvant of choice in the preclinical evaluation of many vaccine candidates in animal models. Although enterotoxic in humans, CT can promote strong mucosal CD4 + T-cell responses to co-administered antigens, that are protective against H pylori infection in mice. 10 Extensive research over the last few years has focused on the generation of non-toxic derivatives of CT while retaining significant adjuvant activity. 11 The multiple mutated cholera toxin (mmCT) is a product of such research and has been developed by introducing multiple mutations in the enzymatically active cholera toxin A subunit (CTA), making it resistant to proteolytic cleavage which is required for the enterotoxicity. 12 A detailed mechanism of adjuvant activity of mmCT has also been recently demonstrated in human in vitro activated co-cultures of T cells and antigen-presenting cells. 13 Furthermore, preclinical studies have shown that mmCT is as effective as CT in promoting mucosal and systemic immune responses to the co-administered model antigen ovalbumin and a H pylori whole cell vaccine and thus seems to be a promising mucosal adjuvant. 14 During vaccination, dendritic cells can take up the vaccine antigens from the delivery site and migrate to the draining lymph node for presentation and activation of CD4 + T cells. Activated and differentiated CD4 + T cells can then migrate back to the mucosal sites including stomach and intestine via the blood guided by the expression of the mucosal tissue-specific integrin molecule α4β7 which binds to the endothelial cell adhesion molecule, mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1). At the mucosal site, the antigen-specific CD4 + α4β7 + T cells can then orchestrate anti-bacterial effector functions. Most studies in mice have focused on evaluation of H pylori vaccine-induced CD4 + T-cell activation and correlates to protection locally in the stomach. However, for vaccine trials in humans, it would be useful to identify immune cell populations in circulation that are related to effective protection against H pylori infection in the stomach. Identification of such correlates of protection would greatly streamline the design and analysis of future vaccine trials.
In the current study, we have analyzed the innate and adaptive immune cell populations in the blood shortly after immunization of mice and correlated the immune cell populations to the levels of bacterial colonization. We report that, while the SL route of immunization with lysate antigens and adjuvant led to an increase in circulating neutrophils and CD62L − memory CD4 + T cells, the IG immunization with H pylori whole cell vaccine (WCV) and adjuvant led to an increase in circulation of inflammatory monocytes, memory CD62L − and CD4 + α4β7 + cells. Protection in immunized mice only correlated with high frequency of CD4 + α4β7 + cells in the circulation but not with the frequency of neutrophils, inflammatory monocytes or memory CD4 + CD62L − T cells (both SL and IG). Furthermore, in accordance with our previous studies, we also confirmed significantly lower bacterial colonization rates in sublingually compared to intragastrically immunized mice. 15 Altogether, the data presented in the current study will be useful for the design and evaluation of a H pylori vaccine in clinical trials in high-risk H pylori-infected individuals/ patients.
| MATERIAL S AND ME THODS

| Animals
Female C57BL/6 mice (8-week-old) were purchased from Taconic and housed in microisolators at the Laboratory for Experimental Biomedicine, University of Gothenburg, Sweden. All experiments were approved by the animal ethics committee of the Gothenburg region.
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| Preparation of inactivated H pylori whole cell vaccine and antigens for immunizations
| Inactivated H pylori bacteria strain Hel 305
Bacteria were grown in Brucella broth as previously described. 16 The bacteria were harvested and washed in PBS and resuspended to an optical density of 1.5. Formaldehyde was added to a final concentration of 0.01 mol/L to the suspension and incubated for 2 hours at 37°C on a slow shaker, and then overnight shaking at room temperature. After washing to remove all formaldehyde, the inactivated bacteria were resuspended in PBS to an optical density of 1.5 and stored at 4°C. Complete inactivation of bacteria was confirmed by plating the bacteria on horse blood agar plates, and no colonies were found growing.
| Lysates
Helicobacter pylori lysate antigens from strain Hel 305 (CagA + VacA + Le x ) were prepared and protein content measured as previously described. 17 Briefly, the H pylori Hel 305 strain of bacteria were was grown on blood agar plates for 48 hours and the bacteria were harvested and resuspended in sterile PBS. The bacterial suspension was then sonicated for 30 minutes (30 seconds pulse at 50% capacity).
The bacterial suspension was placed on ice during the entire sonication time. The protein content in the H pylori Hel 305 lysate was measured using the noninterfering protein assay kit (Calbiochem).
To reduce the volume for sublingual immunization, the H pylori Hel 
| Immunizations
| Intragastric immunizations
Groups of mice were immunized intragastrically on two consecutive days at bi-weekly intervals with OD 0.5 of formalin-killed whole cell bacteria corresponding to 1 × 10 9 bacteria/mL and 7.5 μg of CT (List Biological Laboratories) or 15 μg of mmCT 12 with bicarbonate buffer on each occasion (hereafter referred to as IG + CT or IG + mmCT) ( Figure 3A ).
| Sublingual immunizations
Groups of mice were immunized sublingually twice at a bi-weekly interval with 200 μg of H pylori lysate antigens reconstituted in 7.5 μg of CT or 15 μg of mmCT on each occasion (hereafter referred to as SL + CT or SL + mmCT) ( Figure 3A ). H pylori vaccination regimen (route and vaccine) was carefully chosen based on our previous studies. 14, 18 
| Blood collection and Flow cytometry analysis
Blood was collected from the tail vein pre-immunization (day 0) and on day 4, day 7 after the 1st and day 4, day 7 after the 2nd immunization for phenotypic analysis of leukocytes by multi-pa- 
| Cultivation of H pylori SS1 for infection
The mouse-adapted H pylori Sydney strain 1 (SS1) (CagA + VacA + Le y ) was cultured for infection as described in Ref. 17 . A one-time infectious dose consisting of approximately 3 × 10 8 viable bacteria/mouse was administered intragastrically to each mouse. 19 
| Quantitation of bacteria in the stomach of mice
Immunized and unimmunized control mice were sacrificed 3 weeks after the infection to assess the protection induced by the prophylactic immunizations. The number of bacteria in the stomach was determined by quantitative culture as described previously. 19 
| H pylori antigen-specific cellular immune responses
| Cell culture
Spleens from mice were collected after the sacrifice, and single-cell suspensions were prepared and cultured. 20 In short, cells were plated 
| Proliferation assay
The proliferation of the cells was assessed by incorporation of radioactive thymidine which was added in the last 7 hours of culture as previously described in detail in Ref. ( 18 
| Detection of cytokines
Supernatants were collected before addition of thymidine and stored at −70°C for subsequent cytokine analysis. The cell culture supernatants were analyzed for IL-2, IL-17A, GM-CSF, and IFNγ using the Luminex assay (Bio-Plex Pro Assay; Bio-Rad Laboratories) and analyzed according to the manufacturer's instructions. 
| Statistical and multivariate data analysis
| RE SULTS
| Increased frequency of innate immune cells in circulation after mucosal immunization against H pylori infection in mice
Our aim was to characterize the phenotype of circulating leukocytes in response to mucosal immunization with H pylori antigens and CT or mmCT as an adjuvant administered via sublingual (SL) or intragastric (IG) routes. We first analyzed the frequency of neutrophils (CD11b + Ly6G + ), eosinophils (SSC high Siglec-F + ), and CD11b + Ly6Ginflammatory monocytes (Ly6C hi MHCII neg ) in the blood of mice by multi-parameter flow cytometry at day 0 (pre-immunization), and then day 4, and day 7 after both 1st and 2nd immunization ( Figure 1A) .
In response to the SL + CT immunization, the frequency of circulating CD11b + Ly6G + neutrophils was significantly upregulated at day 4 after 1st immunization (P < .05) and at day 4 (P < .05) after the 2nd
immunization, compared to day 0 ( Figure 1B ). SL + mmCT immunization also induced an increase in circulating neutrophils, and this was significant only day 7 after the 2nd immunization (P < .05). The neutrophil frequency in blood was not affected by IG immunizations. In summary, neutrophils were enhanced in circulation shortly after SL but not IG immunizations, using CT and mmCT as adjuvants in the H pylori vaccine.
Although we found rather small population of Siglec-F + eosinophils in the circulation before vaccination, the frequency of Siglec-F + eosinophils was clearly downregulated from day 4 after the 1st immunization to day 7 after the 2nd immunization compared to day 0 in all groups of mice, except in the SL + CT immunized mice. Statistically significant downregulation in frequency of eosinophils in circulation was found in SL + mmCT, IG + CT, and IG + mmCT immunized mice ( Figure 1C ), suggesting a possible migration of these cells into the gastric mucosal tissue. 7 We next analyzed the frequency of circulating CD11b + Ly6G − inflammatory monocytes (Ly6C int MHCII neg ) using a gating strategy used by Moyat et al 21 and found them to be upregulated after SL + CT immunization day 7 after the 1st immunization (P < .05) and day 4 after the 2nd immunization (P < .05). A similar trend was seen in the SL + mmCT immunized mice, although the data were not statistically significant ( Figure 1D ). The increase in circulating CD11b + Ly6G − inflammatory monocytes was most striking after IG + CT immunization both at day 4 (P < .05) and day 7 (P < .001) after the 1st immunization, and even higher upregulation was observed at day 4 (P < .0001) after the 2nd immunization, compared to day 0. The patterns were similar in Eosinophils   D0  D4  D7  D4  D7  D0  D4  D7  D4  D7  D0  D4  D7  D4  D7  D0  D4  D7  D4  D7  0   5 IG + mmCT immunized mice with significant upregulation of circulating CD11b + Ly6G − inflammatory monocytes at day 4 (P < .001) and day 7 (P < .001) after 1st immunization, and at day 4 (P < .0001) and day 7
(P < .001) after 2nd immunization, compared to day 0. All four groups of immunized mice had the highest peak circulation of CD11b + Ly6G − inflammatory monocytes day 4 after 2nd immunization.
No significant change in the frequencies of neutrophils, eosinophils, or CD11b + Ly6G-inflammatory monocytes was found in the blood of naïve mice at any of the indicated time points (data not shown).
| Increase in the frequency of either circulating memory and migrating CD4 + T cells after immunization via mucosal routes
The crucial role of CD4 + T cells in vaccine-induced protection against H pylori infection has been reported in previous studies. 9, 22 Therefore, we aimed to characterize the phenotype of circulating memory, mucosal and gut homing α 4 β 7 + CD4 + T cells in response to SL and IG immunizations in an attempt to find correlates of protection ( Figure 2A) . The total frequency of circulating CD4 + T cells 
| Mucosal immunization with H pylori antigens and CT or mmCT promotes protection against H pylori infection
In order to evaluate the protection induced by the prophylactic SL and IG immunizations, the same groups of immunized and unimmunized mice analyzed for the frequencies of immune cells in circulation were also infected by gavage with live H pylori SS1 bacteria two weeks after the last immunization. Three weeks post-infection, mice
were sacrificed and the stomachs were collected to determine the numbers of H pylori bacteria (CFU) ( Figure 3A) . When compared to the unimmunized infection control group, the highest level of protection was found after SL + mmCT (P < .0001; mean, 1132-fold reduction) as well as SL + CT immunizations (P < .0001, mean, 868-fold reduction), while significant but not as large reduction in the gastric bacterial loads was found after IG + mmCT (P < .0001; mean, 107fold reduction) as well as IG + CT immunization (P < .0001; mean, 72-fold reduction). The potent adjuvant effect of mmCT in the H pylori vaccine for reducing H pylori bacterial burden in the stomach of mice was completely comparable to when using CT as adjuvant ( Figure 3B) .
We further carried out correlation analysis between the frequency of CD4 + α 4 β 7 + cells in the blood day 4 or day 7 after 1st or 2nd
immunization and the number of bacteria after challenge in the same mouse. We found a significant inverse correlation between the frequency of CD4 + α 4 β 7 + cells in the blood after SL or IG immunization, day 4 after 1st or day 4 and 7 after 2nd immunization and the number of bacteria in the stomach. Thus, mice with a higher frequency of CD4 + α 4 β 7 + cells in the blood early after SL or IG immunization were protected against H pylori infection ( Figure 3C ).
| H pylori antigen-specific proliferation and cytokine responses after sublingual or intragastric immunization
We next investigated the H pylori antigen-specific cellular immune 
| Multivariate analysis reveals clustering of individual mice into groups depending on the route of immunization
We utilized a multivariate discriminant analysis (OPLS-DA) to investigate the relationship between the route of immunization (SL or IG) and immune parameters studied in each mouse (X-variables). The analysis showed that the two immunization groups SL and IG indeed clustered separately from each other based on the differences in bacterial colonization and adaptive immune response parameters (frequency of α4β7 + CD4 + T cells, CD4 + CD62L − day 4 after 1st immunization and proliferation counts (cpm) and cytokine secretion IL-2, IL-17A, GM-CSF, and IFNγ measured at the time of sacrifice (R2 0.522, Q2 0.447) ( Figure 5) ). The clustering of groups of SL and IG immunized was found to be statistically significant (P < .001). A similar analysis, comparing the influence of the adjuvant included in the H pylori vaccine on the bacterial colonization and adaptive immune response (as above), showed that the mice immunized with vaccine and CT or mmCT (square and circle symbols) did not cluster to form distinct groups (R2 = 0.3 and Q2 0.1). In summary, our data show that protection against H pylori infection and the pattern of immune responses was unique to the route of immunization and not the adjuvant CT or mmCT used in the vaccine. Further, the selected immune parameters measured in this study can be used to predict the response to vaccination.
| D ISCUSS I ON
In the current study, we have evaluated immune correlates in the blood to vaccine-induced protection against H pylori infection. We were able to confirm previous findings that the non-toxic adjuvant mmCT was as effective as an adjuvant as native CT in a H pylori vaccine for enhancing antigen-specific T-cell responses and cytokine secretion 14 and report several important new findings, namely that (a) the populations of innate and memory cells are increased in the circulation after vaccination and that (b) the frequency of α4β7 + CD4 + T cells emerging in the blood after 1st and 2nd immunization, irrespective of route or adjuvant correlated inversely with the bacterial load in the stomach of mice. We believe that the results from this study will be useful for the design of a H pylori vaccine and the evaluation of vaccine efficacy in clinical trials.
One of our first observations in vaccinated mice was the increase in the frequency of neutrophils in the blood particularly after SL immunization. This spike in the frequency neutrophils in the blood after Our data show that mmCT is a promising candidate for a safe and effective mucosal adjuvant in a H pylori vaccine due to its non-toxic properties and the ability to induce antigen-specific T-cell activation and cytokines IFNγ, IL-17A, and IL-2 secretion.
The effects of mmCT that we observed on protection have also previously been reported for another non-toxic mucosal adjuvant, the double mutant heat-labile toxin from Escherichia coli (dmLT). 18 The mutations in proteolytic cleavage site of the A subunit in both mmCT and dmLT lead to markedly reduced activity of adenylate cyclase, reduced cAMP levels and fluid secretion when compared to the native toxin. 12 The advantage of mmCT over dmLT is that the mmCT protein can be produced in large quantities from V cholerae with high purity since it is secreted into the extracellular medium compared to dmLT that is found in inclusion bodies and requires additional purification steps which compromises the yield. 12 If mmCT can be produced on an industrial GMP scale and tested for its safety in humans, it could be considered for inclusion in a low cost H pylori vaccine.
In summary, H pylori vaccines containing mmCT administered via mucosal routes lead to increased frequency of several immune cell populations during the prime-boost stage of the vaccination protocol. In particular, the CD4 + α4β7 + T-cell population in the blood correlated with vaccine-induced protection and could potentially serve as a predictor for vaccine efficacy. These results will aid in the rational design and testing of a H pylori vaccine for use in humans. 
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